BioCarta, Inc Company Profile
BioCarta was founded in April 2000 to become the leading developer, supplier and distributor of uniquely sourced and characterized reagents and assays for biopharmaceutical and academic research. Proteomics is a promising new field comprising of the study of protein expression and function. A growing number of companies and institutions see proteomics either as a means of enhancing genomic information or as an alternative route of basic science investigation and drug discovery. Charting a complete map of how proteins act in human health and disease requires several types of analysis in addition to high throughput expression, which provides a general understanding of expression patterns. The next level of proteomic analysis, called functional proteomics, requires methods and tools to precisely and quantitatively determine protein function in normal and disease states. Researchers performing functional proteomic studies will require a large toolbox of well characterized reagents including antibodies, proteins , cells, cell-based assays and other kits to drive their research. Additionally, information on proteomic pathways will be required to stay current with rapid advances in this field. Due to these advances in genomic and proteomic research, our industry has experienced an explosion in the growth in new targets for academic study and drug development. BioCarta aims to be the leader in the development and commercialization of new technology for functional proteomics by creating an international organization geared towards identifying, acquiring, and commercializing novel products. Furthermore, the BioCarta web site serves as an interactive web-based resource for life scientists. A state-of-the-art communication tool, our site provides immediate access to existing life science research and integrates new data as it emerges. Broadly, this information falls into four categories – gene function, proteomic pathways, ePosters, and research reagents. Simultaneously, BioCarta offers an easy and dynamic forum for information exchange and collaboration between researchers, educators and students.
6827 Nancy Ridge Drive
United States of America
Drugs and Medications
7 anterior gradient homolog 2 (AGR2)-inhibited different molecular mutual positive correlation network was constructed in lung adenocarcinoma compared with human normal adjacent tissues by 17 overlapp...
Solute carrier family 2 (facilitated glucose/fructose transporter) member 5 (SLC2A5)-inhibited seven different molecular Pearson mutual-positive-correlation networks constructed by 24 overlapping mole...
BioCarta was founded in April 2000 to become the leading developer, supplier and distributor of uniquely sourced and characterized reagents and assays for biopharmaceutical and academic research. Prot...
Jingmei Biotech is the premier provider of life science research products in China. In 2003, Jingmei merged with two US companies, Orbigen Inc. and BioCarta Inc.. The new company has 14 offices worldw...
More Information about "BioCarta, Inc" on BioPortfolio
We have published hundreds of BioCarta, Inc news stories on BioPortfolio along with dozens of BioCarta, Inc Clinical Trials and PubMed Articles about BioCarta, Inc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioCarta, Inc Companies in our database. You can also find out about relevant BioCarta, Inc Drugs and Medications on this site too.